Roche to Acquire PathAI for ~$1.05B
Roche has signed a definitive agreement to acquire AI‑driven diagnostics firm PathAI for an estimated $1.05 billion, comprising $750 million upfront and up to $300 million in milestones. The deal, slated to close in the second half of 2026, builds on a partnership that began in 2021 and expanded in 2024 to co‑develop AI‑enabled companion diagnostic algorithms. By integrating PathAI’s platform, Roche aims to accelerate automation in digital pathology and deepen its precision‑medicine portfolio. The acquisition also positions Roche to offer AI‑enhanced support for clinical trials and translational research.
Angelini Pharma to Acquire Catalyst Pharmaceuticals for ~$4.1B
Angelini Pharma announced a definitive agreement to acquire Catalyst Pharmaceuticals for $31.5 per share, valuing the deal at roughly $4.1 billion. The transaction, expected to close in the third quarter of 2026, marks Angelini’s first direct entry into the U.S. pharmaceutical...
Artera Secures FDA Clearance for AI-Based Breast Cancer Risk Tool
The U.S. Food and Drug Administration granted clearance to ArteraAI Breast, an AI‑driven digital pathology tool that combines digitized histopathology slides with clinical data to generate a risk score for distant metastasis in early‑stage hormone‑receptor‑positive/HER2‑negative breast cancer. The system stratifies...
BriaCell Therapeutics Reports US FDA IND Clearance to Initiate P-I/II Trial of Bria-BRES+ in Breast Cancer
BriaCell Therapeutics announced that the U.S. Food and Drug Administration has granted IND clearance to launch a combined Phase I/II study of its Bria‑BRES+ therapy in patients with metastatic breast cancer. Preclinical results presented at AACR indicate Bria‑BRES+ stimulates both...
Alebund Pharmaceuticals Completes Patient Enrollment in P-III (RESPOND-2) Trial of AP301 for Hyperphosphatemia
Alebund Pharmaceuticals announced that patient enrollment is complete for its global Phase III RESPOND‑2 trial of AP301, a novel therapy for hyperphosphatemia in dialysis patients. The study enrolled 282 participants—138 in the United States and 144 in China—exceeding the planned 264....
PharmaShots Awards 2026: Honoring Global Market Titans & Healthcare Innovators
The PharmaShots Awards 2026 celebrated global healthcare innovation, recognizing excellence across biopharma, medtech, diagnostics, generics, nutraceuticals, animal health, digital health, and AI‑driven drug discovery. High‑profile companies such as Eli Lilly, Pfizer, AbbVie, Medtronic, Johnson & Johnson, Roche and XtalPi were among the honorees....
Pharmaceutical Packaging Summit 2026 | June 22-23 | Encore Boston Harbor, Boston, MA
The Pharmaceutical Packaging Summit 2026 will convene senior pharma packaging leaders and solution providers at Encore Boston Harbor on June 22‑23. The invitation‑only forum will address regulatory serialization, patient‑centric design, sustainability, smart packaging, supply‑chain resilience, and cost‑efficient innovation. Attendees will...
Caris Launches Caris MI Clarity for AI-Powered Breast Cancer Recurrence Risk Assessment
Caris Life Sciences has introduced Caris MI Clarity, an AI‑driven prognostic test that evaluates both early (0‑5 years) and late (5‑15 years) distant recurrence risk for postmenopausal patients with HR‑positive/HER2‑negative, node‑negative early‑stage breast cancer. The assay analyzes digitized H&E pathology...
Multi4 Medical Receives CE Mark Approval for Multi4 System to Perform Outpatient Bladder Cancer Treatment
Multi4 Medical has secured CE mark approval for its Multi4 System, an integrated endoscopic platform that enables bladder cancer treatment in a single outpatient visit. The device delivers local anesthesia, performs tumor resection, extracts tissue for pathology, and cauterizes—all without...
2026 World Pediatrics Conference | October 05-06 | Osaka, Japan
The 2026 World Pediatrics Conference (2026WPC) will take place in Osaka, Japan on October 5‑6, 2026. The two‑day event gathers pediatricians, nurses, researchers and industry professionals to present the latest findings across a broad spectrum of specialties. Sessions will address neonatal care,...
Key Biosimilars Events of April 2026
In April 2026 the biosimilar landscape saw a wave of regulatory approvals and strategic deals. The European Commission cleared Poherdy (pertuzumab) and Tuyory (tocilizumab), while Health Canada and China’s NMPA approved multiple denosumab biosimilars and granted IND clearances for Henlius’...
Lannett Company and Sunshine Lake Pharma Report US FDA Approval of Langlara (Biosimilar, Lantus)
The U.S. Food and Drug Administration has granted interchangeable biosimilar status to Langlara, a copy of Sanofi’s Lantus insulin glargine. Langlara is approved for adults and children with type 1 diabetes and for adults with type 2 diabetes, based on data showing...
Mirum Pharmaceuticals Reports P-IIb (VISTAS) Trial Data on Volixibat in Primary Sclerosing Cholangitis (PSC) Patients with Cholestatic Pruritus
Mirum Pharmaceuticals announced that its Phase IIb VISTAS trial met the primary endpoint, showing volixibat (20 mg BID) reduced cholestatic pruritus in primary sclerosing cholangitis (PSC) patients by 2.72 points on the Adult ItchRO scale versus a -1.08 point change with...
Ending Prescription Ping-Pong in Specialty Care: Colin Banas, CMO, DrFirst Shares His Vision
DrFirst’s Timely platform embeds AI‑driven benefits verification, prior‑authorization automation, and pharmacy routing directly into the e‑prescribing workflow, aiming to eliminate the “prescription ping‑pong” that stalls specialty medication access. The solution surfaces real‑time cost and coverage data, enabling clinicians to answer...
BioCryst Partners with Irish Affiliate of Neopharmed Gentili in ~$345M EU Commercialization Deal for Navenibart
BioCryst Pharmaceuticals has signed a licensing agreement with the Irish affiliate of Neopharmed Gentili, granting exclusive rights to commercialize its long‑acting plasma kallikrein inhibitor, Navenibart, across the European Union. The deal provides BioCryst with a $70 million upfront payment and potential...
Celcuity Reports the P-III (VIKTORIA-1) Trial Data on Gedatolisib Combination for HR+/HER2- PIK3CA Mutant Advanced Breast Cancer
Celcuity announced phase‑III VIKTORIA‑1 data showing that gedatolisib combined with fulvestrant, with or without palbociclib, achieved a statistically significant improvement in progression‑free survival (PFS) versus the alpelisib‑fulvestrant standard of care in HR+/HER2‑ advanced breast cancer patients harboring PIK3CA mutations. The...
ARCHIMED to Acquire Esperion Therapeutics for ~$1.1B
Archimed announced a definitive agreement to acquire Esperion Therapeutics for up to $1.1 billion, taking the company private and delisting it from NASDAQ. Esperion shareholders will receive $3.16 in cash per share plus a contingent value rights (CVR) package worth roughly...
Rhythm Pharmaceuticals Reports the EC Approval of Imcivree (Setmelanotide) for Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals announced that the European Commission has granted marketing authorization for Imcivree (setmelanotide) to treat acquired hypothalamic obesity in patients aged four years and older. The approval is based on the Phase III TRANSCEND trial, which enrolled 120 participants...
Arvinas and Pfizer Report the US FDA Approval of Veppanu (Vepdegestrant) for ESR1-Mutated Breast Cancer
The U.S. FDA has approved Veppanu (vepdegestrant) for adults with ESR1‑mutated ER+/HER2‑ advanced or metastatic breast cancer who have received at least one line of endocrine therapy. The approval follows the Phase III VERITAC‑2 trial, which compared Veppanu to fulvestrant...
Theradaptive Receives US FDA Approval to Initiate P-III Trial of OsteoAdapt SP for Spinal Fusion Procedures
Theradaptive has secured U.S. FDA approval to launch the pivotal OASIS Phase III trial evaluating its OsteoAdapt SP device as a bone‑graft alternative in transforaminal, anterior, and lateral lumbar interbody fusion (TLIF, ALIF, LLIF) procedures. The trial follows earlier studies involving...
Cue Biopharma Licenses Ascendant-221 From Ascendant Health Sciences in a ~$691.5M Deal
Cue Biopharma announced an exclusive license with Ascendant Health Sciences for Ascendant-221, an anti‑IgE monoclonal antibody aimed at allergic diseases. The agreement grants Cue worldwide rights, except Greater China, in exchange for a $15 million upfront payment and up to $676.5 million...
LEO Pharma to Acquire Replay for Rare Skin Disease Gene Therapy Platform
LEO Pharma has signed a definitive agreement to acquire gene‑therapy specialist Replay for an upfront cash payment of $50 million, with additional milestone fees and tiered single‑digit royalties. Replay brings a herpes simplex virus (HSV) platform that delivers large therapeutic genes...
BeOne Receives the US FDA Priority Review to Tevimbra Combination for 1L Treatment of HER2+ GEA Cancers
The U.S. FDA granted priority review to BeOne Medicines’ Tevimbra‑Ziihera‑chemotherapy regimen for first‑line treatment of unresectable HER2‑positive gastric, gastro‑esophageal junction and esophageal adenocarcinomas. The decision follows the Phase III HERIZON‑GEA‑01 trial, which enrolled 914 patients and compared the new combos against...
Laguna Biotherapeutics Reports the US FDA IND Clearance for LGNA-100 to Treat High-Risk Pediatric Leukemias
Laguna Biotherapeutics announced that the U.S. Food and Drug Administration has granted IND clearance for its lead candidate LGNA-100, allowing the company to begin a Phase‑I single ascending dose trial. The study will evaluate safety, tolerability and mechanism of action...
Huahui Health and BeOne Medicines Partner for HH160 in a ~$2.02B Deal
Huahui Health and BeOne Medicines have signed a global exclusive option, license and collaboration agreement for HH160, a novel trispecific antibody targeting oncology immunotherapy. Huahui will receive $20 million upfront, $100 million when BeOne exercises its option, and up to $1.9 billion in...
Henlius and Organon Receive the EC Approval for Poherdy (Biosimilar, Perjeta)
The European Commission has granted approval for Poherdy, a 420 mg/14 mL interchangeable biosimilar of pertuzumab (Perjeta), covering all approved indications. The decision rests on extensive analytical, pharmacokinetic, efficacy, safety and immunogenicity data that demonstrate equivalence to the reference product. Henlius has...
Teva to Acquire Emalex Biosciences for ~$900M
Teva Pharmaceutical Industries has signed a definitive agreement to acquire Emalex Biosciences for an estimated $900 million, comprising $700 million upfront and up to $200 million in commercial milestones. The purchase brings Emalex’s lead asset, ecopipam—a selective dopamine D1 receptor antagonist—into Teva’s neuroscience...
HUTCHMED Reports NMPA’s NDA Acceptance Under Priority Review for Sovleplenib to Treat wAIHA
HUTCHMED’s oral JAK2 inhibitor sovleplenib has received NDA acceptance and priority review from China’s National Medical Products Administration for warm‑antibody autoimmune hemolytic anemia (wAIHA). The submission is backed by Phase II/III data showing a 43.8% overall response rate versus 0%...
Kestrel Therapeutics Inks AbbVie Deal Worth up to $1.45B with Option to Acquire
Kestrel Therapeutics and AbbVie have signed a warrant‑style agreement valued at up to $1.45 billion. AbbVie will finance the development of KST‑6051, a pan‑KRAS inhibitor for advanced solid tumors, and receives an exclusive option to acquire Kestrel once predefined development and...
The US FDA Grants Priority Review and Breakthrough Therapy Designation to GSK’s Bepirovirsen for Chronic Hepatitis B
The U.S. FDA has accepted GSK’s new drug application for bepirovirsen, granting both priority review and breakthrough therapy designation for chronic hepatitis B. The decision is based on Phase III B‑Well 1 and B‑Well 2 trials across 29 countries, which showed higher functional‑cure...
Eli Lilly to Acquire Ajax Therapeutics for ~$2.3B
Eli Lilly has signed a definitive agreement to acquire Ajax Therapeutics for roughly $2.3 billion in cash, covering an upfront payment and future clinical and regulatory milestones. Ajax’s lead candidate, AJ1‑11095, is a Type II JAK2 inhibitor currently in a Phase‑I trial (AJX‑101)...
Motif Neurotech Receives FDA IDE Approval to Initiate RESONATE Trial of Motif XCS System in Treatment-Resistant Depression
Motif Neurotech has secured FDA Investigational Device Exemption (IDE) to launch the RESONATE early feasibility study of its Motif XCS System in patients with treatment‑resistant depression who have failed at least two medications. The trial will monitor 12‑month safety, symptom...
AstraZeneca Reports FDA Approval of Saphnelo for Systemic Lupus Erythematosus (SLE)
The U.S. Food and Drug Administration has granted approval for AstraZeneca’s Saphnelo autoinjector (anifrolumab, 120 mg weekly) for adult patients with systemic lupus erythematosus (SLE) when used alongside standard of care. The decision follows the Phase III TULIP‑SC trial, which enrolled 367...
Sanofi Reports the CHMP Positive Opinion for Cenrifki (Tolebrutinib) to Treat Non-Relapsing SPMS
Sanofi’s oral BTK inhibitor Cenrifki (tolebrutinib) received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for treating secondary progressive multiple sclerosis (SPMS) without relapses in the past two years. The recommendation is...
Novartis’ Itvisma Receives the CHMP Positive Opinion for Spinal Muscular Atrophy
Novartis’ gene‑replacement therapy Itvisma (onasemnogene abeparvovec) received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for treating patients aged two years and older with 5q spinal muscular atrophy (SMA). The recommendation is...
Sun Pharma to Acquire Organon for ~$11.75B
Sun Pharmaceutical Industries Ltd. announced a definitive agreement to acquire Organon Holding Inc. for $14 per share in an all‑cash transaction, valuing the deal at approximately $11.75 billion. The acquisition will bolster Sun’s innovative medicines portfolio and give it a foothold...
Arrowhead Pharmaceuticals Receives the CHMP’s Positive Opinion for Redemplo (Plozasiran) to Treat Familial Chylomicronemia Syndrome (FCS)
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on Arrowhead Pharmaceuticals’ RNAi therapy Redemplo (plozasiran) as an adjunct to diet for adults with familial chylomicronemia syndrome (FCS). The recommendation follows the Phase III...
Mabwell Initiates P-III Trial for 9MW2821 in TNBC
Mabwell has launched a Phase III trial of its Nectin‑4‑targeting antibody‑drug conjugate 9MW2821 in patients with locally advanced or metastatic triple‑negative breast cancer (TNBC). The study pits 9MW2821 against the investigator’s choice of chemotherapy in patients who have already received taxane‑based...
FLEX Vascular Presents 12-Month Real-World Data for FLEX Vessel Prep System at CX Symposium 2026
FLEX Vascular unveiled 12‑month real‑world outcomes from its FLEX FIRST AV Registry at the Charing Cross Symposium 2026. In a cohort of 130 hemodialysis access patients, the FLEX Vessel Prep System showed zero serious adverse events at 30 days and durable...
Johnson & Johnson Reports Clinical Findings on Imaavy (Nipocalimab) for Generalized Myasthenia Gravis (gMG) at AAN 2026
Johnson & Johnson presented Phase III Vivacity‑MG3 data on its anti‑IgG antibody, Imaavy (nipocalimab), in generalized myasthenia gravis (gMG). In the 24‑week post‑hoc analysis, patients receiving Imaavy plus standard of care were about four times more likely to achieve sustained...
Regeneron Reports the US FDA Accelerated Approval of Otarmeni (Lunsotogene Parvec-Cwha) in Genetic Hearing Loss
Regeneron’s Otarmeni (lunsotogene parvec‑cwha) received FDA accelerated approval for treating severe to profound sensorineural hearing loss caused by biallelic OTOF gene variants. The therapy, provided free of charge in the U.S., was evaluated in a Phase I/II CHORD trial of...
DemeRx Reports the US FDA IND Application Acceptance to Advance DMX-1001 for Alcohol Use Disorder
DemeRx announced that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for DMX-1001, an oral formulation of noribogaine, to treat alcohol use disorder (AUD). The company recently completed a multiple‑ascending‑dose (MAD) trial in healthy...
Regeneron and Sanofi Report the US FDA Approval of Dupixent (Dupilumab) for Chronic Spontaneous Urticaria (CSU)
Regeneron and Sanofi announced that the U.S. Food and Drug Administration has approved Dupixent (dupilumab) for chronic spontaneous urticaria (CSU) in patients as young as two years old who remain symptomatic despite H1 antihistamines. The decision is based on two...
Merck Partners with Google Cloud in ~$1B Deal to Build AI-Enabled Enterprise Platform
Merck has signed a multi‑year agreement with Google Cloud valued at up to $1 billion to build an AI‑driven, agentic enterprise platform covering research, manufacturing, commercial and corporate functions. The collaboration will embed Google’s Gemini Enterprise and other generative AI tools...
AstraZeneca Reports the P-III (I CAN) Trial Data on Ultomiris for IgA Nephropathy
AstraZeneca announced interim Phase III (I CAN) data for Ultomiris in IgA nephropathy, enrolling about 510 high‑risk adults. The trial met its primary endpoint, showing a roughly 30% reduction in 24‑hour proteinuria at 34 weeks, with benefits evident as early as 10...
Utepreva Launches Utepreva Endometrial Sampler to Support Early Diagnosis of Endometrial Cancer
Utepreva has introduced the Utepreva Endometrial Sampler, a single‑use device aimed at improving tissue capture for early endometrial cancer diagnosis, slated for market release in October 2026. The sampler integrates a sponge tip, plunger‑driven suction, and a collection chamber to...
Regeneron Reports P-III (NIMBLE) Trial Data on Cemdisiran for Generalized Myasthenia Gravis (gMG)
Regeneron presented Phase III (NIMBLE) data showing that subcutaneous cemdisiran 600 mg every 12 weeks significantly improved symptoms in adults with generalized myasthenia gravis (gMG) and anti‑AChR antibodies. Over 24 weeks, the cemdisiran arm reduced MG‑ADL scores by 4.5 points versus 2.2...
Ipsen’s Ojemda (Tovorafenib) Receives Conditional Approval for R/R BRAF-Altered Pediatric Low-Grade Glioma (pLGG) in the EU
Ipsen’s oral kinase inhibitor Ojemda (tovorafenib) received conditional approval from the European Commission for treating pediatric low‑grade glioma (pLGG) with BRAF fusions, rearrangements or V600 mutations. The indication applies to patients six months or older who have progressed after at...
Genentech Reports the P-III (METEOROID) Trial Data on Enspryng (Satralizumab) to Treat MOGAD
Genentech presented Phase III METEOROID trial results for Enspryng (satralizumab) in patients aged 12 and older with myelin oligodendrocyte glycoprotein antibody‑associated disease (MOGAD). The study met its primary endpoint, showing 87% of participants remained relapse‑free at 48 weeks versus 67%...
Sanofi Reports the US FDA Approval of Tzield to Delay Onset of Stage 3 Type 1 Diabetes in Children (≥1years)
Sanofi’s monoclonal antibody Tzield (teplizumab‑mzwv) received U.S. FDA approval under priority review to delay the onset of stage 3 type 1 diabetes (T1D) in children as young as one year who are diagnosed with stage 2 disease. The decision was driven by one‑year...